Stuttgart
30.10.26 | 16:33
18,550 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 18,450 | 18,930 | 17:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.10. | Earnings Call: XVIVO wächst im 3. Quartal 2026 kräftig - Markteinführung des Herztransplantationssystems schreitet voran | 2 | Investing.com Deutsch | ||
| 22.10. | Xvivo Perfusion AB Q3 Income Climbs | 2 | RTTNews | ||
| 22.10. | Xvivo Perfusion AB: Interim Report January - September 2026 | 145 | GlobeNewswire (Europe) | Third quarter 2026 (Jul-Sep)• Net sales amounted to SEK 252.6 million (189.1), corresponding to a growth of 34 percent in SEK.• Organic growth was 32 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 14.10. | XVIVO Perfusion AB: Conference call on Interim Report July-September 2026 | 304 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / October 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report July-September 2026.... ► Artikel lesen | |
| 30.09. | Nomination Committee of XVIVO Perfusion AB | 346 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / September 30, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The following members have been appointed to XVIVO Perfusion's nomination committee for the... ► Artikel lesen | |
| 28.09. | XVIVO Perfusion AB: XVIVO Announces FDA Receipt of PMA Application for The XVIVO Heart Assist Transport System | 2.513 | ACCESS Newswire | CAUTION-Investigational device in the US. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established. The XVIVO heart technology... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 20.08. | XVIVO erhält CE-Zertifikate für bahnbrechende Technologie zur Herzkonservierung | 13.383 | news aktuell | Göteborg/Berlin (ots) - - Die CE-Zertifizierungen ermöglichen den breiteren Einsatz der innovativen XVIVO-Technologie und verbessert den Zugang zu Herztransplantationen in Europa. XVIVO gibt die CE-Zertifizierungen... ► Artikel lesen | |
| 11.08. | Xvivo Perfusion AB: XVIVO receives CE certificates for its groundbreaking heart preservation technology, transforming access to life-saving transplants across Europe | 962 | GlobeNewswire (Europe) | CAUTION-Investigational device in the US. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established. The XVIVO heart technology... ► Artikel lesen | |
| 03.08. | XVIVO Perfusion AB: XVIVO Granted Additional Patient Enrollment in the US PRESERVE CAP Study for XVIVO Heart Assist Transport | 458 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / August 3, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO announces that the US Food and Drug Administration (FDA) has granted the company approval... ► Artikel lesen | |
| 14.07. | Xvivo Perfusion AB (publ) reports Q2 results | 3 | Seeking Alpha | ||
| 14.07. | Xvivo Perfusion AB Q2 Profit Rises | 3 | RTTNews | ||
| 14.07. | XVIVO übertrifft im Q2 die Umsatzerwartungen dank starkem Thorax-Geschäft | 2 | Investing.com Deutsch | ||
| 14.07. | XVIVO Perfusion AB: Interim Report January - June 2026 | 635 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth... ► Artikel lesen | |
| 09.07. | OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S. | 470 | Business Wire | OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ procurement organization... ► Artikel lesen | |
| 26.06. | XVIVO Perfusion AB: Conference call on Interim Report April-June 2026 | 519 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The... ► Artikel lesen | |
| 18.05. | XVIVO Perfusion AB: Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology | 445 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of... ► Artikel lesen | |
| 27.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 361 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV):The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
| 24.04. | XVIVO Perfusion AB: Interim Report January - March 2026 | 253 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding to growth... ► Artikel lesen | |
| 24.04. | Xvivo Perfusion AB: Interim Report January - March 2026 | 303 | GlobeNewswire (Europe) | First quarter 2026 (Jan-Mar)• Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.• Organic growth was 23 percent in local currencies. Excluding revenue from... ► Artikel lesen | |
| 22.04. | XVIVO Perfusion AB: XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion In Direct Procurement DCD Heart Transplantation | 584 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT... ► Artikel lesen |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,435 | +1,63 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler Erhält GMP-Zertifizierung für Actinium-225 | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Zulassungsgenehmigung
Eckert & Ziegler Erhält GMP-Zertifizierung für Actinium-225
28.10.2026 / 14:00 CET/CEST
Für den... ► Artikel lesen | |
| INTUITIVE SURGICAL | 393,55 | -2,21 % | ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes? | ||
| RHOEN-KLINIKUM | 14,400 | 0,00 % | EQS-PVR: RHÖN-KLINIKUM AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: RHÖN-KLINIKUM Aktiengesellschaft
RHÖN-KLINIKUM AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung... ► Artikel lesen | |
| BICO GROUP | 2,230 | +1,59 % | Cellink mit EILMELDUNG: Folgt jetzt der nächste Kursrutsch? - Jetzt handeln, noch vor Börsenschluss! | ||
| EUROFINS SCIENTIFIC | 87,76 | +1,22 % | Eurofins Scientific SE: Eurofins Scientific: Director/PDMR Shareholding | Eurofins Scientific SE (Paris:ERF) (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each... ► Artikel lesen | |
| M1 KLINIKEN | 19,580 | -0,61 % | Drohnenauftrag für Volatus, KI-Strom treibt Infineon und Beauty-Boom bei M1 Kliniken: Drei spannende Aktien im Check | Drohnen fürs kanadische Militär, Chips für den KI-Boom und Schönheitsbehandlungen mit satten Margen: Börsenfantasie hat viele Gesichter. Volatus Aerospace könnte mit einem kanadischen Militärauftrag... ► Artikel lesen | |
| BAXTER | 20,510 | -2,43 % | Baxter Reports Profit In Q3; Raises 2026 Financial Outlook | DEERFIELD (dpa-AFX) - Baxter International Inc. (BAX) reported third quarter net income to shareholders of $294 million compared to a loss of $46 million, prior year. Income per share from continuing... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| JD HEALTH INTERNATIONAL | 4,366 | +7,78 % | JD HEALTH Partners with Pfizer to Explore Integrated Pharmaceutical and Healthcare Service Model | ||
| COOPER COMPANIES | 53,45 | -1,20 % | Cooper Companies to replace CEO, reshuffle board members | ||
| LIFEWARD | 5,910 | -3,11 % | Lifeward Ltd. - 8-K, Current Report | ||
| BONESUPPORT | 29,620 | +2,70 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q3 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the third quarter 2026.
"Strong growth and important progress... ► Artikel lesen | |
| NATERA | 372,30 | -4,51 % | Natera, Inc.: Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer | Natera's oncology portfolio featured in 25 ESMO abstracts including 9 oral presentations, with publications in Nature Medicine and ESMO Open Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free... ► Artikel lesen | |
| NANO-X IMAGING | 0,318 | +3,89 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| IMPLANTICA | 5,910 | -3,27 % | Implantica AG: Implantica announces leading U.S. surgeon participates in RefluxStop training surgeries | Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, today announced that Dr. John C. Lipham, Professor of Surgery at the University of Southern... ► Artikel lesen |
XVIVO PERFUSION AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 18,550 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.